Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People
Reads0
Chats0
TLDR
Short-term phentermine administration induced significant weight reduction and reduction of waist circumference without clinically problematic adverse events on relatively healthy Korean obese people.Abstract:
2or greater. They received phentermine-HCl 37.5 mg or placebo once daily with behavioral therapy for obesity. The primary endpoints were the changes of body weight and waist circumference from the baseline in the intention-to-treat population. Mean decrease of both body weight and waist circumference in phentermine-treated subjects were significantly greater than that of placebo group (weight: -6.7 ± 2.5 kg, p < 0.001; waist circumference: -6.2 ± 3.5 cm, p < 0.001). Significant number of subjects in phentermine group accomplished weight reduction of 5% or greater from the baseline and 10% or more (p < 0.001). There were no significant differences in systolic and diastolic blood pressure between the groups (p = 0.122 for systolic BP; p = 0.219 for diastolic BP). Dry mouth and insomnia were the only statistically significant adverse events that occurred more frequently in phentermine group. Most side effects of phentermine were mild to moderate in intensity. Short-term phentermine administration induced significant weight reduction and reduction of waist circumference without clinically problematic adverse events on relatively healthy Korean obeseread more
Citations
More filters
Journal ArticleDOI
American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.
W. Timothy Garvey,Jeffrey I. Mechanick,Elise M. Brett,Alan J. Garber,Daniel L. Hurley,Ania M. Jastreboff,Karl Nadolsky,Rachel Pessah-Pollack,Raymond A Plodkowski +8 more
TL;DR: The final recommendations recognize that obesity is a complex, adiposity-based chronic disease, where management targets both weight-related complications and adiposity to improve overall health and quality of life.
Journal ArticleDOI
The Science of Obesity Management: An Endocrine Society Scientific Statement.
George A. Bray,William E Heisel,Ashkan Afshin,Michael D. Jensen,William H. Dietz,Michael W. Long,Robert F. Kushner,Stephen R. Daniels,Thomas A. Wadden,Adam G. Tsai,Frank B. Hu,John M. Jakicic,Donna H. Ryan,Bruce M. Wolfe,Thomas H. Inge,Thomas H. Inge +15 more
TL;DR: Clinicians should consider body fat distribution and individual health risks in addition to body mass index when making treatment decisions, especially when treatment is discontinued.
Journal ArticleDOI
Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association
Harold E. Bays,Peter P. Toth,Penny M. Kris-Etherton,Nicola Abate,Louis J. Aronne,W. Virgil Brown,J. Michael Gonzalez-Campoy,Steven R. Jones,Rekha B. Kumar,Ralph La Forge,Varman T. Samuel +10 more
TL;DR: On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dys Lipidemia.
Journal ArticleDOI
Obesity: Pathophysiology and Management.
TL;DR: Benefit-to-risk balance should guide treatment decisions and several medical devices are available for short-term and long-term use.
Journal ArticleDOI
A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.
Andy Wolff,Revan Kumar Joshi,Jörgen Ekström,Doron J. Aframian,Anne Marie Lynge Pedersen,Gordon Proctor,Nagamani Narayana,Alessandro Villa,Ying Wai Sia,Ardita Aliko,Richard McGowan,Alexander Ross Kerr,Siri Beier Jensen,Arjan Vissink,Colin Dawes +14 more
TL;DR: A comprehensive list of medications with documented effects on salivary gland function or symptoms that may assist practitioners in assessing patients who complain of dry mouth while taking medications is compiled.
References
More filters
Journal Article
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults : the evidence report
Journal ArticleDOI
Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
TL;DR: The risk of death from all causes, cardiovascular disease, cancer, or other diseases increases throughout the range of moderate and severe overweight for both men and women in all age groups.
Journal ArticleDOI
Excess deaths associated with underweight, overweight, and obesity.
TL;DR: For example, this paper found that obesity was associated with 111 909 excess deaths (95% confidence interval [CI], 53 754170 064) and underweight with 33 746 excess deaths.
Journal ArticleDOI
Excess deaths associated with underweight, overweight, and obesity
TL;DR: Underweight and obesity, particularly higher levels of obesity, were associated with increased mortality relative to the normal weight category and these findings are consistent with the increases in life expectancy in the United States and the declining mortality rates from ischemic heart disease.
Journal ArticleDOI
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
Richard B. Rothman,Michael H. Baumann,Christina M. Dersch,Dana V. Romero,Kenner C. Rice,F. Ivy Carroll,John S. Partilla +6 more
TL;DR: In vitro methods determined the neurochemical mechanism of action of amphetamine, 3,4‐methylenedioxymethamphetamine (MDMA), (+)‐methamphetamine, ephedrine, phentermine, and aminorex, and demonstrated that the most potent effect of these stimulants is to release NE.